tiprankstipranks
Rhythm Pharmaceuticals Inc (MX:RYTM)
:RYTM
Mexico Market
RYTM
Rhythm Pharmaceuticals
RESEARCH TOOLSreports

Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

RYTM Analyst Ratings

Strong Buy
16Ratings
Strong Buy
15 Buy
1 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Rhythm
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RYTM Stock 12 Month Forecast

Average Price Target

$2,383.90
▲(58.93% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is $2,383.90 with a high forecast of $2,703.94 and a low forecast of $1,774.46. The average price target represents a 58.93% change from the last price of $1,500.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1499":"$1,499","2704":"$2,704","1800.25":"$1,800.3","2101.5":"$2,101.5","2402.75":"$2,402.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2703.9359168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.70K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2383.8997516475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.38K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1774.4579454,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.77K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1499,1800.25,2101.5,2402.75,2704],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1500,1592.6104551384615,1685.2209102769232,1777.8313654153847,1870.4418205538461,1963.0522756923078,2055.6627308307693,2148.273185969231,2240.8836411076923,2333.494096246154,2426.1045513846157,2518.715006523077,2611.3254616615386,{"y":2703.9359168,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1500,1567.9922885882693,1635.9845771765386,1703.9768657648078,1771.969154353077,1839.9614429413464,1907.9537315296154,1975.9460201178847,2043.938308706154,2111.930597294423,2179.9228858826928,2247.9151744709616,2315.907463059231,{"y":2383.8997516475,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1500,1521.1121496461537,1542.2242992923077,1563.3364489384614,1584.4485985846154,1605.5607482307691,1626.6728978769231,1647.7850475230769,1668.8971971692308,1690.0093468153846,1711.1214964615385,1732.2336461076923,1753.3457957538462,{"y":1774.4579454,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1819.7,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1800,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1800,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1866.76,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1866.76,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1866.76,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1850,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1500,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1500,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1500,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1500,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1500,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1500,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2,704Average Price Target$2,384Lowest Price Target$1,774
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on MX:RYTM
David Hoang
Deutsche Bank
Deutsche Bank
$2,027.95
Hold
35.20%
Upside
Initiated
08/27/26
Rhythm Pharmaceuticals initiated with a Hold at Deutsche BankRhythm Pharmaceuticals initiated with a Hold at Deutsche Bank
Guggenheim Analyst forecast on MX:RYTM
Seamus Fernandez
Guggenheim
Guggenheim
$2,416.64
Buy
61.11%
Upside
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (NASDAQ: GLUE) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Morgan Stanley Analyst forecast on MX:RYTM
Michael Ulz
Morgan Stanley
Morgan Stanley
$2,534.94
Buy
69.00%
Upside
Reiterated
08/24/26
Rhythm Pharmaceuticals: Buy Rating Reiterated as Japan Approval Extends Imcivree Growth, $150 Price Target Unchanged
J.P. Morgan Analyst forecast on MX:RYTM
Priyanka Grover
J.P. Morgan
J.P. Morgan
$2,467.34
Buy
64.49%
Upside
Reiterated
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Viatris (NASDAQ: VTRS)
Citizens JMP Analyst forecast on MX:RYTM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$2,619.44→$2,703.94
Buy
80.26%
Upside
Reiterated
08/05/26
Rhythm Pharmaceuticals price target raised to $160 from $155 at CitizensRhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
Canaccord Genuity Analyst forecast on MX:RYTM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$2,551.84→$2,602.54
Buy
73.50%
Upside
Reiterated
08/05/26
Rhythm Pharmaceuticals price target raised to $154 from $151 at CanaccordRhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
Citi Analyst forecast on MX:RYTM
Samantha Semenkow
Citi
Citi
$2,399.74→$2,416.64
Buy
61.11%
Upside
Reiterated
08/05/26
Citi Remains a Buy on Rhythm Pharmaceuticals (RYTM)
Needham Analyst forecast on MX:RYTM
Joseph Stringer
Needham
Needham
$2,196.95
Buy
46.46%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on MX:RYTM
Phil Nadeau
TD Cowen
TD Cowen
$2,196.95
Buy
46.46%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Bank of America Securities Analyst forecast on MX:RYTM
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2,518.04
Buy
67.87%
Upside
Reiterated
08/04/26
Imcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
RBC Capital Analyst forecast on MX:RYTM
Lisa Walter
RBC Capital
RBC Capital
$2,382.84→$2,619.44
Buy
74.63%
Upside
Reiterated
08/04/26
Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on MX:RYTM
Derek Archila
Wells Fargo
Wells Fargo
$2,619.44
Buy
74.63%
Upside
Assigned
07/16/26
Wells Fargo Releases a Buy Rating on Rhythm Pharmaceuticals (RYTM)
H.C. Wainwright Analyst forecast on MX:RYTM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$1,774.46
Buy
18.30%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged
Stifel Nicolaus Analyst forecast on MX:RYTM
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$2,247.65
Buy
49.84%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Belite Bio, Inc. ADR (NASDAQ: BLTE)
Jefferies Analyst forecast on MX:RYTM
Dennis Ding
Jefferies
Jefferies
$2,112.45
Buy
40.83%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on MX:RYTM
David Hoang
Deutsche Bank
Deutsche Bank
$2,027.95
Hold
35.20%
Upside
Initiated
08/27/26
Rhythm Pharmaceuticals initiated with a Hold at Deutsche BankRhythm Pharmaceuticals initiated with a Hold at Deutsche Bank
Guggenheim Analyst forecast on MX:RYTM
Seamus Fernandez
Guggenheim
Guggenheim
$2,416.64
Buy
61.11%
Upside
Reiterated
08/24/26
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (NASDAQ: GLUE) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Morgan Stanley Analyst forecast on MX:RYTM
Michael Ulz
Morgan Stanley
Morgan Stanley
$2,534.94
Buy
69.00%
Upside
Reiterated
08/24/26
Rhythm Pharmaceuticals: Buy Rating Reiterated as Japan Approval Extends Imcivree Growth, $150 Price Target Unchanged
J.P. Morgan Analyst forecast on MX:RYTM
Priyanka Grover
J.P. Morgan
J.P. Morgan
$2,467.34
Buy
64.49%
Upside
Reiterated
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Viatris (NASDAQ: VTRS)
Citizens JMP Analyst forecast on MX:RYTM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$2,619.44→$2,703.94
Buy
80.26%
Upside
Reiterated
08/05/26
Rhythm Pharmaceuticals price target raised to $160 from $155 at CitizensRhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
Canaccord Genuity Analyst forecast on MX:RYTM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$2,551.84→$2,602.54
Buy
73.50%
Upside
Reiterated
08/05/26
Rhythm Pharmaceuticals price target raised to $154 from $151 at CanaccordRhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
Citi Analyst forecast on MX:RYTM
Samantha Semenkow
Citi
Citi
$2,399.74→$2,416.64
Buy
61.11%
Upside
Reiterated
08/05/26
Citi Remains a Buy on Rhythm Pharmaceuticals (RYTM)
Needham Analyst forecast on MX:RYTM
Joseph Stringer
Needham
Needham
$2,196.95
Buy
46.46%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on MX:RYTM
Phil Nadeau
TD Cowen
TD Cowen
$2,196.95
Buy
46.46%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Bank of America Securities Analyst forecast on MX:RYTM
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2,518.04
Buy
67.87%
Upside
Reiterated
08/04/26
Imcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
RBC Capital Analyst forecast on MX:RYTM
Lisa Walter
RBC Capital
RBC Capital
$2,382.84→$2,619.44
Buy
74.63%
Upside
Reiterated
08/04/26
Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on MX:RYTM
Derek Archila
Wells Fargo
Wells Fargo
$2,619.44
Buy
74.63%
Upside
Assigned
07/16/26
Wells Fargo Releases a Buy Rating on Rhythm Pharmaceuticals (RYTM)
H.C. Wainwright Analyst forecast on MX:RYTM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$1,774.46
Buy
18.30%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals: Buy Rating Reiterated on Promising PWS Data and Large Market Opportunity; $105 Price Target Unchanged
Stifel Nicolaus Analyst forecast on MX:RYTM
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$2,247.65
Buy
49.84%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Rhythm Pharmaceuticals (NASDAQ: RYTM) and Belite Bio, Inc. ADR (NASDAQ: BLTE)
Jefferies Analyst forecast on MX:RYTM
Dennis Ding
Jefferies
Jefferies
$2,112.45
Buy
40.83%
Upside
Reiterated
06/15/26
Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARDXArdelyx
ZVRAZevra Therapeutics
HROWHarrow Health
KURAKura Oncology
SNDXSyndax Pharmaceuticals
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Rhythm Pharmaceuticals

3 Months
Whitney IjemCanaccord Genuity
Success Rate
18/25 ratings generated profit
72%
Average Return
+14.86%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +14.86% per trade.
1 Year
Joseph StringerNeedham
Success Rate
36/38 ratings generated profit
95%
Average Return
+69.84%
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +69.84% per trade.
2 Years
Joseph StringerNeedham
Success Rate
36/38 ratings generated profit
95%
Average Return
+158.87%
Copying Joseph Stringer's trades and holding each position for 2 Years would result in 94.74% of your transactions generating a profit, with an average return of +158.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RYTM Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
18
10
8
6
0
Buy
24
19
22
22
17
Hold
0
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
29
30
29
18
In the current month, RYTM has received 17 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. RYTM average Analyst price target in the past 3 months is 2,383.90.
Each month's total comprises the sum of three months' worth of ratings.

RYTM Financial Forecast

RYTM Earnings Forecast

Next quarter’s earnings estimate for RYTM is -$12.33 with a range of -$14.42 to -$9.67. The previous quarter’s EPS was -$12.39. RYTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.
Next quarter’s earnings estimate for RYTM is -$12.33 with a range of -$14.42 to -$9.67. The previous quarter’s EPS was -$12.39. RYTM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Sales Forecast

Next quarter’s sales forecast for RYTM is $1.42B with a range of $1.32B to $1.58B. The previous quarter’s sales results were $1.21B. RYTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.
Next quarter’s sales forecast for RYTM is $1.42B with a range of $1.32B to $1.58B. The previous quarter’s sales results were $1.21B. RYTM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RYTM has Performed in-line its overall industry.

RYTM Stock Forecast FAQ

What is MX:RYTM’s average 12-month price target, according to analysts?
Based on analyst ratings, Rhythm Pharmaceuticals Inc’s 12-month average price target is 2,383.90.
    What is MX:RYTM’s upside potential, based on the analysts’ average price target?
    Rhythm Pharmaceuticals Inc has 58.93% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Rhythm Pharmaceuticals Inc a Buy, Sell or Hold?
          Rhythm Pharmaceuticals Inc has a consensus rating of Strong Buy, which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Rhythm Pharmaceuticals Inc’s share price target?
            The average share price target for Rhythm Pharmaceuticals Inc is 2,383.90. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $2,703.94 ,and the lowest forecast is $1,774.46. The average share price target represents 58.93% Increase from the current price of $1,500.
              What do analysts say about Rhythm Pharmaceuticals Inc?
              Rhythm Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of Rhythm Pharmaceuticals Inc?
                To buy shares of MX:RYTM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.